Company Description
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States.
It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform.
The company’s product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials.
It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors.
NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
| Country | MD |
| Founded | 2011 |
| IPO Date | Feb 12, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Ms. Kristi Jones R.Ph. |
Contact Details
Address: 9119 Gaither Road Gaithersburg, Maryland 20878 United States | |
| Phone | 301-825-9810 |
| Website | neximmune.com |
Stock Details
| Ticker Symbol | NEXI |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001538210 |
| CUSIP Number | 65344D109 |
| ISIN Number | US65344D2080 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Kristi Jones R.Ph. | Chief Executive Officer, President and Director |
| Dr. Mathias Oelke Ph.D. | Chief Scientific Officer |
| John Trainer M.B.A. | Consultant |
| Timothy Stover | Vice President, Corporate Controller and Principal Financial and Accounting Officer |
| Karen Haslbeck | Head of Human Resources |
| Dr. Daniel P. Bednarik | Senior Vice President of Molecular Engineering and Protein Design |
| Dr. Robert Douglas Knight M.D. | Chief Medical Officer |
| Chad Rubin | Senior Vice President of Corporate Affairs |
| Dr. Jack A. Ragheb M.D., Ph.D. | Senior Vice President of Translational Science |
| Matthew Schiller | Head of Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 19, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jul 19, 2024 | 8-K | Current Report |
| Jul 11, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jul 11, 2024 | 8-K | Current Report |
| Jun 21, 2024 | DEF 14A | Other definitive proxy statements |
| Jun 11, 2024 | PRE 14A | Other preliminary proxy statements |
| Jun 11, 2024 | 8-K | Current Report |
| May 20, 2024 | 10-Q | Quarterly Report |
| May 15, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Apr 16, 2024 | 10-K | Annual Report |